The role of interleukin-1 beta as an early biomarker for renal dysfunction in Egyptian sickle cell disease patients Authors: Nourhan Mohamed Nasr, Noha Khalifa Abd El Ghaffar, Shaimaa Mohamed El Asmar, Yasmin Mohamed Saber Published: 2026 ABSTRACT BackgroundSickle cell nephropathy is a recognized complication increasingly seen in young individuals with sickle cell disease (SCD). The typical progression of glomerular disease is thought to involve hyperfiltration and albuminuria, eventually leading to a decline in glomerular filtration rates and ultimately end-stage renal disease (ESRD). This study sought to investigate the relationship between urinary interleukin-1 beta (IL-1β), a marker of inflammation, and existing biomarkers of renal damage in SCD patients. The goal was to identify IL-1β as a novel, early diagnostic biomarker for sickle nephropathy.Patients and methodsThis case-control study enrolled forty-six patients (both genders, aged 18–40 years) with sickle cell disease and forty-six healthy controls. All patients were subjected to the following: A complete medical history, physical examination, and laboratory investigation including a complete blood analysis, blood chemistry (which included kidney function tests and liver function, serum ferritin, urinalysis, hepatitis B surface antigen and hepatitis C antibody, estimated GFR, urinary IL-1 beta using the ELISA technique, and urinary albumin/creatinine ratio). These measurements were taken for both the case and control groups.ResultsThe mean estimated glomerular filtration rate (eGFR) level showed a statistically significant increase in SCD patients. The median value of the albumin/creatinine ratio level was statistically different between cases and controls. The median value of urinary IL-1 beta level was statistically different between cases and controls. Assessment of correlations between urinary IL-1 beta and eGFR revealed a statistically significant negative correlation between them, while assessment of the correlation between urinary IL-1 beta and the urinary albumin/creatinine ratio revealed a statistically significant positive correlation between them in sickle cell patients.ConclusionIn this study, significant renal hyperfiltration, a high frequency of albuminuria, and elevated urine IL-1β levels are all present in Egyptian adults with sickle cell disease. Urinary IL-1β, albuminuria, and eGFR are strongly correlated, highlighting the crucial role of inflammation in sickle cell nephropathy pathogenesis. A promising non-invasive biomarker for early renal injury and disease progression in sickle cell disease (SCD) may be urinary IL-1β. Introduction Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy that affects over 300,000 infants globally each year. This term encompasses various genetic alterations, such as homozygous and heterozygous mutations, and instances where it’s inherited alongside other hemoglobin disorders. The resulting abnormalities in red blood cells trigger a cascade of complications impacting multiple organ systems. Its pathology involves processes like vaso-occlusive events, ischemic organ damage, reperfusion injury, endothelial dysfunction, vasculopathies, and oxidative stress, among other contributing elements [1]. Sickle cell anemia (SCA) can impact the kidneys in various ways. Individuals with SCA often experience hyposthenuria, a defect in urine concentration, and may have elevated glomerular filtration rates (GFR) alongside enhanced proximal tubular function. They can also exhibit a reduced capacity to acidify urine or excrete potassium. Furthermore, SCA patients may develop microscopic hematuria or even gross hematuria due to renal papillary necrosis [2, 3]. In sickle nephropathy (SN), focal and segmental glomerulosclerosis is the most frequently observed glomerular lesion over time, though membranous glomerulopathy has also been documented in certain instances. Research indicates that gross proteinuria and ESRD manifest in 15–30% of individuals with SCA. Nevertheless, not all SCA patients develop SN, and the specific factors that predict or accelerate its progression in predisposed individuals remain unclear [4, 5]. When evaluating SN, traditional indicators of kidney damage are often unhelpful in the early stages. For instance, plasma creatinine levels appear low in SN patients due to an unusually high excretion of creatinine in the urine. As a result, elevated serum creatinine only becomes apparent in the advanced phases of the disease. Patients with SCA also exhibit higher-than-normal GFR and renal blood flow, leading to an elevated urinary creatinine clearance caused by hyperfiltration. A subnormal GFR and increased serum creatinine only develop once significant proteinuria manifests [6]. Furthermore, estimating GFR based on creatinine clearance or serum creatinine levels in SCA is prone to error. This is because of the high creatinine excretion characteristic of SCA, along with variations in muscle mass and hydration status. Consequently, early interventions that could prevent the progression of kidney damage often can’t be implemented, as SN is typically diagnosed at a point where the renal damage is already widespread and largely irreversible [7]. The SCN biomarkers, including plasma cystatin C, renal injury molecule-1 (KIM-1), nephrin, monocyte chemoattractant protein-1 (MCP-1), and IL-1 beta, are among those that can aid in the early diagnosis of vascular injury, endothelial dysfunction, tubulo-glomerular damage, oxidative stress, and other related complications [8]. IL-1β is a key mediator of the inflammatory response and shows a huge complexity. In addition to being essential for host response and resistance to pathogens, it also exacerbates the damage caused by chronic disease and acute tissue injury, as is the case in SCD [9, 10]. A previous study reported that there was an association between plasma IL-1β concentration and increased incidence of stroke in sickle cell patients [11]. To our knowledge, very few studies have investigated the urinary IL-1β concentration association with SCD in our area. This study is the first one done in patients with sickle cell anemia to assess the relationship between urinary IL-1 beta and other established biomarkers of renal impairment in SCD patients, such as serum creatinine, albuminuria, and estimated glomerular filtration rate. This study aimed to comprehensively evaluate renal involvement in patients with sickle cell disease (SCD) through the assessment of estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR), in comparison with healthy controls. In addition, this work aimed to investigate the potential association between urinary IL-1β levels and renal function parameters, including eGFR and ACR, in order to explore the role of IL-1β as a non-invasive biomarker for early detection of sickle cell nephropathy. Patient and methods This research has been designed as a case-controlled study that follows the Institutional Committee regulations for the Protection of Human Subjects that were adopted by the 18th World Medical Assembly, Helsinki, Finland. The study protocol was applied for approval by the Ethical Committee of Fayoum University (Clinical trial number: not applicable). Inclusion criteria for all subjects: Sickle cell patients aged > 18 diagnosed by hemoglobin electrophoresis. The control group consisted of healthy individuals > 18 years recruited from the Fayoum University outpatient hematology clinic. Exclusion criteria of all subjects: diabetic patients, hypertensive patients, and organ and bone marrow transplant patients. The research did not include patients with any organ failure, cardiac conditions, neoplasms, or clinical or laboratory signs of past and present renal illness. Every patient underwent the following procedures: A thorough medical history that includes information on age, sex, consanguinity, duration of illness, blood transfusions, vaso-occlusive crises, frequency of hospital admission, history of infection, history of splenectomy, urine symptoms, and complications; a physical examination that includes vital signs, body weight, body mass index, pallor, jaundice, and an abdominal examination to detect hepatomegaly and splenomegaly; and laboratory testing that includes. Complete blood analysis using Sysmex XN 1000 for the measurement of hemoglobin (Hb), total leucocytic count (TLC), and platelets.Blood chemistry, which includes kidney function tests (urea, creatinine, and BUN) and liver function tests (albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)), all measured with an A c 311 automated chemistry analyzer, Roche HITACHI, Mannheim, 724 − 0030, Germany.Serum ferritin.urinalysis.Hepatitis B surface antigen and hepatitis C antibody.Estimated GFR for all patients using the MDRD(modification of diet in renal disease) equation.IL-1 beta was measured in all cases and controls using the ELISA technique kit from SineGeneClon Biotech Co., Ltd, China.Albumin/creatinine ratio measured for both case and control groups. Complete blood analysis using Sysmex XN 1000 for the measurement of hemoglobin (Hb), total leucocytic count (TLC), and platelets. Complete blood analysis using Sysmex XN 1000 for the measurement of hemoglobin (Hb), total leucocytic count (TLC), and platelets. Blood chemistry, which includes kidney function tests (urea, creatinine, and BUN) and liver function tests (albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)), all measured with an A c 311 automated chemistry analyzer, Roche HITACHI, Mannheim, 724 − 0030, Germany. Blood chemistry, which includes kidney function tests (urea, creatinine, and BUN) and liver function tests (albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST)), all measured with an A c 311 automated chemistry analyzer, Roche HITACHI, Mannheim, 724 − 0030, Germany. Serum ferritin. Serum ferritin. urinalysis. urinalysis. Hepatitis B surface antigen and hepatitis C antibody. Hepatitis B surface antigen and hepatitis C antibody. Estimated GFR for all patients using the MDRD(modification of diet in renal disease) equation. Estimated GFR for all patients using the MDRD(modification of diet in renal disease) equation. IL-1 beta was measured in all cases and controls using the ELISA technique kit from SineGeneClon Biotech Co., Ltd, China. IL-1 beta was measured in all cases and controls using the ELISA technique kit from SineGeneClon Biotech Co., Ltd, China. Albumin/creatinine ratio measured for both case and control groups. Albumin/creatinine ratio measured for both case and control groups. Statistical analysis The statistical software for the social sciences (SPSS) version 28 (IBM Corp., Armonk, NY, USA) was used to code and enter the data. Frequencies (number of cases) and relative frequencies (percentages) for categorical variables, as well as mean and standard deviation for normally distributed quantitative variables and median and interquartile range for non-normally distributed quantitative variables, were used to summarize the data. For normally distributed quantitative variables, the unpaired t test or analysis of variance (ANOVA) with multiple comparisons post hoc test was used to compare groups; for non-normally distributed quantitative variables, the non-parametric Kruskal-Wallis test and Mann-Whitney test were utilized. The Chi square (2) test was used to compare categorical data. When the expected frequency was fewer than five, an exact test was employed. The Spearman correlation coefficient was used to find correlations between quantitative variables.In order to determine the optimal cutoff value of relevant markers for the identification of nephropathy in cases, an ROC curve was created using area under the curve analysis. P-values were deemed statistically significant if they were less than 0.05. Results This study included two groups: Group 1 46 patients of both genders with sickle cell disease, aged > 18 years. Group 2 The control group included 46 healthy subjects with the age and gender matched to the patient group. Patient demographic and baseline characteristics Demographic data of the study population are shown in (Tables 1 and 3). In this study, the mean age of SCD patients was 24.67 ± 6.70 years. There were 21 female patients and 25 male patients. There were 19 with sickle thalassemia, and 27 had sickle cell disease. The median age at diagnosis among cases was 5 years, with a median duration of illness of 17 years. Patients received blood transfusions at a median interval of 8 weeks (IQR: 4–24 weeks).Table 1Comparison between cases and controlCount%Patient subgroupsSickle thalassemia1941.3%Sickle cell disease2758.7%CasesControlP valueCount%Count%Sexfemale2145.7%2554.3%0.404male2554.3%2145.7%consanguinityyes3371.7%00.0%------no1328.3%00.0%frequency of hospital admissionon transfusion2247.8%00.0%------frequently12.2%00.0%on crisis time1941.3%00.0%not frequent48.7%00.0%stable510.9%00.0%no2963.0%46100.0%HSMyes4597.8%00.0%< 0.001no12.2%46100.0%no00.0%46100.0%Strokeyes12.2%00.0%1no4597.8%46100.0%VOCyes3882.6%00.0%< 0.001no817.4%46100.0%Priapismyes12.2%00.0%1no4597.8%46100.0%Hemolytic crisisyes24.3%00.0%0.495no4495.7%46100.0%Acute chest syndromeyes12.2%00.0%------no46100.0%46100.0%complicationyes4291.3%00.0%< 0.001no48.7%46100.0%hydroxyureatreated with hydroxyurea1941.3%00.0%------no treatment2758.7%00.0%Hematuriayes36.5%00.0%0.242No4393.5%46100.0%HCV Abyes510.9%00.0%0.056No4189.1%46100.0%HBV AbNo46100.0%46100.0%-------*Statistically significant at p ≤ 0.05 Table 1Comparison between cases and controlCount%Patient subgroupsSickle thalassemia1941.3%Sickle cell disease2758.7%CasesControlP valueCount%Count%Sexfemale2145.7%2554.3%0.404male2554.3%2145.7%consanguinityyes3371.7%00.0%------no1328.3%00.0%frequency of hospital admissionon transfusion2247.8%00.0%------frequently12.2%00.0%on crisis time1941.3%00.0%not frequent48.7%00.0%stable510.9%00.0%no2963.0%46100.0%HSMyes4597.8%00.0%< 0.001no12.2%46100.0%no00.0%46100.0%Strokeyes12.2%00.0%1no4597.8%46100.0%VOCyes3882.6%00.0%< 0.001no817.4%46100.0%Priapismyes12.2%00.0%1no4597.8%46100.0%Hemolytic crisisyes24.3%00.0%0.495no4495.7%46100.0%Acute chest syndromeyes12.2%00.0%------no46100.0%46100.0%complicationyes4291.3%00.0%< 0.001no48.7%46100.0%hydroxyureatreated with hydroxyurea1941.3%00.0%------no treatment2758.7%00.0%Hematuriayes36.5%00.0%0.242No4393.5%46100.0%HCV Abyes510.9%00.0%0.056No4189.1%46100.0%HBV AbNo46100.0%46100.0%-------*Statistically significant at p ≤ 0.05 Comparison between cases and control *Statistically significant at p ≤ 0.05 About 91.3% of the patients had different complications, and the most obvious one is occlusive crisis about 82.6%. About 6.5% of patients had hematuria, 2.2% of patients had a stroke, 2.2% of patients had priapism, 2.2% of patients had hemolytic crisis, and 2.2% of patients had acute chest syndrome. About 41% of patients received hydroxyurea. The median frequency of vaso-occlusive crises (VOCs) was 6 per year (IQR: 3–9) . Laboratory parameters are shown in (Tables 2 and 3). The mean hemoglobin level was significantly lower statistically in SCD patients than in controls, as the mean hemoglobin level of SCD patients was 8.70 ± 1.42 g/dl, while the mean hemoglobin level of the control group was 13.17 ± 1.18 g/dl.Table 2Laboratory investigations of the study groupsCasesControlMeanStandard DeviationMeanStandard DeviationP valueAge24.596.6526.677.000.146BW60.616.7468.858.33< 0.001*BMI23.791.9925.442.15< 0.001*Hb (g/dl)8.701.4213.171.18< 0.001*Albumin(g/dl)4.080.294.160.240.149Urea (mg/dl)22.337.3316.742.72< 0.001*Creatinine(mg/dl)0.550.180.590.120.200BUN10.143.377.771.31< 0.001*e GFR(mL/ min/ 1.73 m^2)137.3714.86114.787.19< 0.001**Statistically significant at p ≤ 0.05Table 3Laboratory investigations of the study groupsCasesControlP valueMedian1st quartile3rd quartileMedian1st quartile3rd quartileage of diagnosis (Years)5.004.007.00...duration of illness (Years)17.0016.0022.00...blood transfusion interval ( weeks)8.004.0024.00...Frequency of VOC ( per Years)6.003.009.00TLC(10^3 /µL)11.659.2016.008.756.0010.50< 0.001*PlT(10^3/µL)295.50189.00425.00362.50256.00416.000.254ALT(U/L)27.0018.0037.0018.0015.0020.00< 0.001*AST(U/L)30.5027.0040.0024.0023.0028.00< 0.001*Ferritin(ng/mL)639.00445.101500.0030.0019.0039.00< 0.001*Urinary IL 1 beta (pg/ml)1.751.442.201.080.761.30< 0.001*Urinary Albumin /creatinine ratio191.7888.13360.7521.8815.0327.50< 0.001**Statistically significant at p ≤ 0.05 Table 2Laboratory investigations of the study groupsCasesControlMeanStandard DeviationMeanStandard DeviationP valueAge24.596.6526.677.000.146BW60.616.7468.858.33< 0.001*BMI23.791.9925.442.15< 0.001*Hb (g/dl)8.701.4213.171.18< 0.001*Albumin(g/dl)4.080.294.160.240.149Urea (mg/dl)22.337.3316.742.72< 0.001*Creatinine(mg/dl)0.550.180.590.120.200BUN10.143.377.771.31< 0.001*e GFR(mL/ min/ 1.73 m^2)137.3714.86114.787.19< 0.001**Statistically significant at p ≤ 0.05 Laboratory investigations of the study groups *Statistically significant at p ≤ 0.05 Table 3Laboratory investigations of the study groupsCasesControlP valueMedian1st quartile3rd quartileMedian1st quartile3rd quartileage of diagnosis (Years)5.004.007.00...duration of illness (Years)17.0016.0022.00...blood transfusion interval ( weeks)8.004.0024.00...Frequency of VOC ( per Years)6.003.009.00TLC(10^3 /µL)11.659.2016.008.756.0010.50< 0.001*PlT(10^3/µL)295.50189.00425.00362.50256.00416.000.254ALT(U/L)27.0018.0037.0018.0015.0020.00< 0.001*AST(U/L)30.5027.0040.0024.0023.0028.00< 0.001*Ferritin(ng/mL)639.00445.101500.0030.0019.0039.00< 0.001*Urinary IL 1 beta (pg/ml)1.751.442.201.080.761.30< 0.001*Urinary Albumin /creatinine ratio191.7888.13360.7521.8815.0327.50< 0.001**Statistically significant at p ≤ 0.05 Laboratory investigations of the study groups *Statistically significant at p ≤ 0.05 The mean urea and BUN levels showed statistically significant increases in cases, as the mean urea level of SCD patients was 22.33 ± 7.33 mg/dl, while the mean urea level of the controls was 16.74 ± 2.72 mg/dl. The mean estimated glomerular filtration rate (eGFR) level showed a statistically significant increase in SCD patients, as the mean eGFR level of SCD patients was 137.37 ± 14.36 mL/min/1.73 m2, while the mean eGFR level of controls was 114.78 ± 7.19 ± mL/min/1.73 m2. The median serum ferritin level showed a statistically significant increase in cases, as the median serum ferritin of SCD patients was 639.00 ng/mL (IQR: 455.1–1500), while the median serum ferritin of the control group was 30.00 ng/mL (IQR: 19–39). Also, the median serum ALT and AST showed a statistically significant increase in cases. In the current study, the median value of the albumin/creatinine ratio level was statistically different between cases and controls, as the median value of the albumin/creatinine ratio was 191.78 (IQR: 88.13-360.75), while in the controls it was 21.88 (IQR: 15.03–27.50). The median urinary IL-1 beta level of SCD patients was 1.7 pg/mL (IQR: 1.44–2.2), while the median urinary IL-1 beta level of the controls was 1.08 pg/mL (IQR: 0.76–1.3), which showed statistically significant increases in SCD patients. Correlation between urinary IL-1 beta, urinary albumin /creatinine ratio and eGFR in sickle cell anemia Assessment of correlations between urinary IL-1 beta and the urinary albumin/creatinine ratio revealed a statistically significant positive correlation between them in sickle cell patients (Fig. 1), while assessment of the correlation between urinary IL-1 beta and eGFR revealed a statistically significant negative correlation between them in sickle cell patients (Fig. 2). Assessment of correlations between the urinary albumin/creatinine ratio and eGFR revealed a statistically significant negative correlation between them in the patient group (Table 4).Table 4Correlation between eGFR, urinary IL-1 beta and urinary albumin /creatinine ratio in sickle cell anemiaSickle cell diseaseUrinary IL 1 betae GFRe GFRCorrelation Coefficient-0.508-1.000P value0.007*.N2727Urinary Albumin /creatinine ratioCorrelation Coefficient0.792-0.503-P value< 0.001*0.008*N2727*Statistically significant at p ≤ 0.05Fig. 1Correlation between urinary IL-1 beta and urinary albumin /creatinine ratio in sickle cell anemiaFig. 2Correlation between urinary IL-1 beta and eGFR in sickle cell anemia Table 4Correlation between eGFR, urinary IL-1 beta and urinary albumin /creatinine ratio in sickle cell anemiaSickle cell diseaseUrinary IL 1 betae GFRe GFRCorrelation Coefficient-0.508-1.000P value0.007*.N2727Urinary Albumin /creatinine ratioCorrelation Coefficient0.792-0.503-P value< 0.001*0.008*N2727*Statistically significant at p ≤ 0.05 Correlation between eGFR, urinary IL-1 beta and urinary albumin /creatinine ratio in sickle cell anemia *Statistically significant at p ≤ 0.05 Correlation between urinary IL-1 beta and urinary albumin /creatinine ratio in sickle cell anemia Correlation between urinary IL-1 beta and eGFR in sickle cell anemia According to the KDIGO guidelines [12], albuminuria is classified into three categories based on the urine albumin-creatinine ratio (UACR), so we classified patients based on KDIGO guidelines into three groups: 5 patients had normal to mildly increased albuminuria, 25 patients had moderately increased albuminuria, and 16 patients had severely increased albuminuria (Fig. 3). By assessment of correlations between the urinary albumin/creatinine ratio and urinary IL-1 beta in each group, we found a statistically significant positive correlation between them in all patient groups (Table 5). Post hoc pairwise comparisons revealed that the severely increased albuminuria (A3) (previouslymacroalbuminuria) group varied significantly from both the normal to mildly increased albuminuria (A1) group (p = 0.002) and the moderately increased albuminuria (A2) (formerly called microalbuminuria) group (p = 0.030). Although there was no significant difference between the normal to mildly increased albuminuria (A1) and moderately increased albuminuria (A2) groups (p = 0.185).Table 5Correlations between Albuminuria and Urinary IL 1 beta in different subgroups of albuminuriaAlbuminuriaA1A2A3P valueMedian1st quartile3rd quartile1st quartile3rd quartileMedian1st quartile3rd quartileUrinary IL 1 beta1.231.201.301.651.441.932.281.862.600.001*Statistically significant at p ≤ 0.05Fig. 3Post hoc pairwise comparisons between different subgroups of albuminuria Table 5Correlations between Albuminuria and Urinary IL 1 beta in different subgroups of albuminuriaAlbuminuriaA1A2A3P valueMedian1st quartile3rd quartile1st quartile3rd quartileMedian1st quartile3rd quartileUrinary IL 1 beta1.231.201.301.651.441.932.281.862.600.001*Statistically significant at p ≤ 0.05 Correlations between Albuminuria and Urinary IL 1 beta in different subgroups of albuminuria *Statistically significant at p ≤ 0.05 Post hoc pairwise comparisons between different subgroups of albuminuria ROC analysis showed that a urinary IL-1 beta value > 1.55 pg/ml had the best cut-off point to differentiate between normal to mildly increased albuminuria (A1) and moderately increased albuminuria (A2) (formerly called microalbuminuria) in cases, with 64% sensitivity and 100% specificity, and a urinary IL-1 beta value > 1.889 pg/ml had the best cut-off point to differentiate between moderately increased albuminuria (A2) and severely increased albuminuria (A3) (previously macroalbuminuria) in cases, with 75% sensitivity and 72% specificity (Figs. 4 and 5).Fig. 4ROC curve to detect the best cutoff value of urinary IL-1 beta in differentiation between normal to mildly increased albuminuria (A1) and moderately increased albuminuria (A2)Fig. 5ROC curve to detect the best cutoff value of urinary IL-1 beta in differentiation between moderately increased albuminuria (A2) and severely increased albuminuria (A3) ROC curve to detect the best cutoff value of urinary IL-1 beta in differentiation between normal to mildly increased albuminuria (A1) and moderately increased albuminuria (A2) ROC curve to detect the best cutoff value of urinary IL-1 beta in differentiation between moderately increased albuminuria (A2) and severely increased albuminuria (A3) Discussion Sickle cell nephropathy is a serious and often underrecognized complication of sickle cell disease, contributing significantly to morbidity and mortality. This condition encompasses a broad spectrum of renal abnormalities, ranging from early tubular dysfunction and glomerular hyperfiltration to progressive proteinuria, chronic kidney disease, and ultimately end-stage kidney disease. Given the insidious onset of renal damage in patients with sickle cell disease, early recognition, risk factor assessment, and timely intervention are essential to improving outcomes. In our study, about 84.4% of sickle cell patients had vas-occlusive crisis, 6.7% of patients had hematuria, 2.2% of patients had a stroke, 2.2% of patients had priapism, 2.2% of patients a hemolytic crisis, and 2.2% of patients had acute chest syndrome. This goes with Oladapo et al. (2020) who told that VOCs are common complications of SCD, affecting a subset of patients who often experience recurrent VOC episodes requiring professional health care [13]. The vaso-occlusive crisis in sickle cell disease is due to the young sticky erythrocytes containing hemoglobin S attaching to the walls of capillary venules, leading to narrowing of their lumens, which leads to the decrease in blood velocity and an increase in erythrocyte transient time; therefore, Hb S becomes deoxygenated, and subsequent erythrocyte sickling occurs. Moreover, necrosis of the affected vascular area and inflammatory response are initiated, which produce pain [14]. Serum ferritin levels were markedly elevated in SCD patients compared with controls. Elevated ferritin reflects chronic hemolysis, iron overload from repeated transfusions, and systemic inflammation. Ferritin also acts as an acute-phase reactant and may contribute to oxidative stress and endothelial injury, further exacerbating renal damage [15]. In the present study, SCD patients significantly higher estimated glomerular filtration rate (eGFR) compared with healthy controls, despite normal serum creatinine levels. Similarly, Derebali et al. who found hyperfiltration is common in SCD, present in most children with sickle cell anemia [16]. Glomerular filtration rate progressively declines with age, with an annual rate of decline of kidney function of 1.27 ± 1.97 ml/min/1.7 m2 reported in African-American adults [17]. Agata et al. 2014 noted that in patients with sickle cell disease, due to the internal medulla microenvironment being hypoxic, acidic, and hyperosmolar, polymerization of deoxygenated hemoglobin S results in RBC sickling and microinfarction causing reduced medullary blood flow, but if the hypoxia deteriorates, prostaglandins are released causing marked vasodilation and glomerular hyperfiltration [18]. A key finding of this study is the significantly elevated urinary interleukin-1 beta (IL-1β) levels in SCD patients compared with controls. IL-1 β is a key mediator of the inflammatory response and shows a huge complexity. In addition to being essential for host response and resistance to pathogens, it also exacerbates the damage caused by chronic disease and acute tissue injury, as is the case in SCD [10, 19]. Although data specifically addressing urinary IL-1β in SCD are limited, prior studies have demonstrated elevated urinary inflammatory and tubular injury biomarkers in SCD patients with albuminuria [20]. However, a previous study by Liao et al. (2022) showed that elevated IL-1β levels were significantly higher in the diabetic nephropathy group than the healthy control group. Collectively, these results strongly support the existence of a robust association between interleukin-1β and nephropathy, regardless of the underlying cause. The increased urinary IL-1β observed in this study likely reflects intrarenal inflammatory activity rather than systemic inflammation alone [21]. According to the KDIGO guidelines, albuminuria is classified into three categories based on the urine albumin-creatinine ratio (UACR). A1 represents normal to mildly increased albuminuria and is defined as a UACR of less than 30 mg/g, indicating minimal kidney damage. A2, known as moderately increased albuminuria (formerly called microalbuminuria), is defined as a UACR of 30–300 mg/g and suggests early but significant kidney involvement. A3, or severely increased albuminuria (previously macroalbuminuria), is defined as a UACR of greater than 300 mg/g and is associated with a high risk of chronic kidney disease progression and cardiovascular events. These albuminuria categories are combined with GFR stages in KDIGO guidelines to determine overall CKD severity and guide treatment decisions [12]. In the current study, albuminuria was significantly higher among SCD patients compared with controls. When classified according to KDIGO guidelines, the majority of patients fell into moderately (A2) or severely increased (A3) albuminuria categories. Urinary IL-1β showed a significant ability to distinguish between patients with moderately elevated albuminuria and those without albuminuria in the current study. The optimal balance between sensitivity and specificity was achieved with a cut-off value of > 1.55 pg/mL, yielding 64% sensitivity and 100% specificity. Elevated urinary IL-1β above this level is strongly associated with true renal involvement rather than false-positive findings, according to the high specificity, which shows that this threshold is highly effective in accurately identifying patients without albuminuria. Additionally, it was shown that urinary IL-1β could differentiate between moderately and severely elevated albuminuria. A higher cut-off value of > 1.889 pg/mL produced 75% sensitivity and 72% specificity, suggesting a fair compromise between minimizing misclassification and accurately identifying patients with advanced renal damage. This result supports the idea that IL-1β expression indicates the degree of renal damage in sickle cell nephropathy by indicating a progressive rise in urinary IL-1β levels with worsening albuminuria. The present study demonstrated a strong positive correlation between urinary IL-1β levels and urinary albumin-creatinine ratio (UACR), indicating that increased renal inflammation is associated with greater glomerular permeability and albumin loss. This finding was consistent across all KDIGO albuminuria categories, suggesting that inflammation contributes to renal injury even in early stages of nephropathy. In addition, the observed negative correlation between urinary IL-1β and eGFR suggests a potential link between inflammatory burden and transition from hyperfiltration to declining renal function. These findings support previous models proposing that inflammation, endothelial dysfunction, and hyperfiltration collectively drive the progression of sickle cell nephropathy [22, 23]. The biological plausibility of urinary IL-1β as a marker of disease progression rather than just an early indicator of renal involvement is supported by the progressive increase in optimal cut-off values across albuminuria stages. This is consistent with the inflammatory condition of sickle cell nephropathy, where endothelial dysfunction, chronic hypoxia, and recurrent vaso-occlusive episodes result in persistent activation of inflammatory pathways, including IL-1β signaling. Increased cytokine production and urine excretion are anticipated as glomerular and tubular injury progresses. Early detection of inflammatory activity the SCN is crucial from the clinical point of view because prompt implementation of renoprotective measures, such as optimizing hydroxyurea therapy, controlling blood pressure, and using renin-angiotensin system blockers, may slow the development of chronic kidney disease. Furthermore, given the growing interest in anti-inflammatory strategies for SCD, IL-1β may serve as both a biomarker and a possible therapeutic target. Limitations and future directions Despite these important findings, this study has limitations, including the relatively small sample size and its cross-sectional design, which precludes causal inference. Longitudinal studies with larger cohorts are needed to determine whether urinary IL-1β can predict renal disease progression and long-term outcomes in patients with SCD. Conclusion The present study highlights a strong association between urinary IL-1β and albuminuria severity in sickle cell nephropathy, reinforcing the role of inflammation in renal damage and supporting the potential utility of urinary IL-1β as an early and non-invasive biomarker of renal involvement in sickle cell disease.